Espa?ol
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Chronic Myelomonocytic Leukemia (CMML)
Shortages of blood cells cause many of the symptoms in people with chronic myelomonocytic leukemia (CMML). Hematopoietic growth factors are hormone-like substances that stimulate bone marrow to make more blood cells. These substances occur naturally in the body, but they can also be made in the lab in large amounts. This lets patients get larger doses of these growth factors than their body would normally make.
Giving a person growth factor drugs is one way to raise low blood cell counts. But transfusions of blood components (red blood cells or platelets) are typically used more often. Growth factor drugs are usually given by subcutaneous (under the skin) injections.
Epoetin alfa (Epogen or Retacrit) is a manmade version of the growth factor erythropoietin, which tells the body to make more red blood cells. It can often help lower the number of red blood cell transfusions a person needs. Giving both epoetin and G-CSF (see "Growth factors to raise white blood cells") can sometimes improve the person's response to epoetin.
Darbepoetin alfa (Aranesp) is a long-acting form of epoetin. It works in the same way can be given less often.
Luspatercept (Reblozyl) isn’t a growth factor, but it is another medicine that can help the body make more healthy red blood cells. Known as a red blood cell maturation agent, this drug affects TGF-β proteins in the bone marrow. TGF-β proteins normally help control how quickly new cells in the bone marrow mature into functioning red blood cells, so that there aren’t too many or too few of them in the body. By acting on specific TGF-β proteins, luspatercept helps the bone marrow make more healthy, fullgrown red blood cells.
Granulocyte colony? stimulating factor (G-CSF, filgrastim, Neupogen or other brand names) can improve white blood cell production. This is not used routinely to prevent infections, but it can help some patients whose main problem is a shortage of white blood cells and who have frequent infections.
Pegfilgrastim (Neulasta, other brand names) is a long-acting form of G-CSF. It works in the same way but can be given less often.
Drugs called thrombopoietin-receptor agonists, such as romiplostim (Nplate) and eltrombopag (Promacta) might help some people with CMML who have very low platelet levels.
A drug called oprelvekin (interleukin-11, IL-11, or Neumega) can be used to raise platelet counts after chemotherapy and in some other diseases. But for most people with CMML, this drug has not been found to be very helpful.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Myelodysplastic Syndromes. Version 1.2024. Accessed at https://www.nccn.org on May 18, 2024.
Padron E. Chronic myelomonocytic leukemia: Management and prognosis. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/chronic-myelomonocytic-leukemia-management-and-prognosis on May 18, 2024.
Sekeres MA, Platzbecker U. Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/myelodysplastic-syndromes-neoplasms-mds-management-of-hematologic-complications-in-lower-risk-mds on May 18, 2024.
Last Revised: May 21, 2024
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
If this was helpful, donate to help fund patient support services, research, and cancer content updates.